類風濕性關節炎藥物市場規模、佔有率、成長分析（按分子、銷售管道、給藥途徑和地區）- 產業預測，2025 年至 2032 年

2023 年全球類風濕性關節炎藥物市場規模為 258 億美元，預計將從 2024 年的 273.5 億美元成長到 2032 年的 435.9 億美元，預測期內（2025-2032 年）的複合年成長率為 6.0%。

受關節炎和關節併發症盛行率上升的推動，全球類風濕性關節炎藥物市場正在經歷顯著成長。類風濕性關節炎盛行率的增加、相關藥物的需求、專利到期以及生物相似藥的出現等因素對於此擴張至關重要。人口老化、傳統緩解疾病藥物（DMARD）使用量的增加以及政府為提高公眾意識和鼓勵創新治療研究而採取的積極舉措進一步加強了市場活力。與知名產業參與者的合作以及活性化的醫療改革力度正在推動這些治療方法的研究和應用。協同效應聯合治療的趨勢也越來越受到支持，因為患者可以從多方面的治療方法中受益匪淺。

目錄

介紹

• 調查目的
• 研究範圍
• 定義

調查方法

• 資訊採購
• 二次資料和一次資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分機會分析

市場動態與展望

• 市場概覽
• 市場規模
• 市場動態
  • 促進因素和機會
  • 限制與挑戰
• 波特的分析

關鍵市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場吸引力指數（2024年）
• PESTEL分析
• 總體經濟指標
• 價值鏈分析
• 定價分析
• 監管格局
• 案例研究
• 技術分析

類風濕性關節炎藥物市場規模（依分子）

• 市場概覽
• 製藥
  • 非類固醇消炎劑
  • 止痛藥
  • 抗風濕藥物
  • 糖皮質激素
• 生物製藥
  • 生物製藥
    • TNF-α拮抗劑
    • T細胞抑制劑
    • CD20抗體
    • JAK抑制劑
    • 抗IL6生物製藥
  • 生物相似藥
    • CD20抗原
    • TNF-α拮抗劑

類風濕性關節炎治療市場規模（依銷售管道）

• 市場概覽
• 處方箋
• 場外交易（OTC）

類風濕性關節炎治療市場規模（依給藥途徑）

• 市場概覽
• 口服
• 腸外

類風濕性關節炎治療市場規模

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業市場定位（2024年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市場佔有率分析（2024年）
• 主要企業簡介
  • 公司詳情
  • 產品系列分析
  • 公司分部佔有率分析
  • 收益與前一年同期比較對比（2022-2024 年）

主要企業簡介

• AbbVie Inc.（USA）
• Pfizer Inc.（USA）
• Amgen Inc.（USA）
• Eli Lilly and Company（USA）
• Bristol-Myers Squibb Company（USA）
• Johnson & Johnson（USA）
• Novartis AG（Switzerland）
• F. Hoffmann-La Roche Ltd（Switzerland）
• UCB SA（Belgium）
• Takeda Pharmaceutical Company Limited（Japan）
• Astellas Pharma Inc.（Japan）
• Eisai Co., Ltd.（Japan）
• Chugai Pharmaceutical Co., Ltd.（Japan）
• Kyowa Kirin Co., Ltd.（Japan）
• Sun Pharmaceutical Industries Ltd.（India）
• Lupin Limited（India）
• Zydus Lifesciences Limited（India）
• Cipla Ltd.（India）
• Dr. Reddy's Laboratories Ltd.（India）

結論和建議

Global Rheumatoid Arthritis Drugs Market size was valued at USD 25.8 billion in 2023 and is poised to grow from USD 27.35 billion in 2024 to USD 43.59 billion by 2032, growing at a CAGR of 6.0% during the forecast period (2025-2032).

The global rheumatoid arthritis drugs market is experiencing significant growth, driven by the rising incidence of arthritis and joint complications. Factors such as the increasing prevalence of rheumatoid arthritis, the demand for related medications, patent expirations, and the emergence of biosimilars are pivotal in this expansion. The ageing population, combined with a greater utilization of conventional Disease-Modifying Anti-Rheumatic Drugs (DMARDs) and proactive government initiatives to enhance public awareness and encourage innovative treatment research, further bolster market dynamics. Collaborations with prominent industry players and increased healthcare reforms are fostering research and adoption of these therapies. The trend towards combination therapies, offering synergistic benefits, is also gaining traction, catering to patients who can significantly benefit from a multifaceted treatment approach.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Rheumatoid Arthritis Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Rheumatoid Arthritis Drugs Market Segments Analysis

Global Rheumatoid Arthritis Drugs Market is segmented by Molecule, Sales Channel, Route of Administration and region. Based on Molecule, the market is segmented into Pharmaceuticals and Biopharmaceuticals. Based on Sales Channel, the market is segmented into Prescription and Over-the-Counter (OTC). Based on Route of Administration, the market is segmented into Oral and Parenteral. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Rheumatoid Arthritis Drugs Market

The growing prevalence of rheumatoid arthritis worldwide serves as a significant driver for the expansion of the global rheumatoid arthritis drugs market. With an aging population and changing dietary habits contributing to the rise in cases of this debilitating condition, there is an increasing demand for effective treatment solutions. This heightened need for innovative and efficient therapies underscores the urgency for advancements in this sector, thereby fostering market growth. As efforts to address the challenges of rheumatoid arthritis continue to evolve, the global market for related pharmaceuticals is poised for significant development in response to these pressing healthcare needs.

Restraints in the Global Rheumatoid Arthritis Drugs Market

Concerns regarding the safety of long-term use of certain rheumatoid arthritis medications, particularly biologics and JAK inhibitors, present a significant challenge to the growth of the market. Both patients and healthcare professionals often hesitate to utilize these therapies due to potential adverse effects, including an increased risk of infections, cardiovascular issues, and cancer. This reluctance impacts the rate at which these treatments are adopted and integrated into clinical practice, ultimately slowing their acceptance and market penetration. As a result, these safety apprehensions create a notable restraint on the overall expansion of the global rheumatoid arthritis drugs market.

Market Trends of the Global Rheumatoid Arthritis Drugs Market

The global rheumatoid arthritis drugs market is experiencing a significant trend towards the adoption of biologic therapies, which encompass advanced treatments such as monoclonal antibodies and Janus kinase (JAK) inhibitors. These innovative drugs are gaining traction due to their targeted mechanisms of action, offering enhanced efficacy and a favorable safety profile compared to traditional therapies. As healthcare providers and patients increasingly recognize the benefits of biologics in managing moderate to severe rheumatoid arthritis, their market penetration continues to rise. This shift towards biologic treatments is poised to reshape the landscape of rheumatoid arthritis therapeutics, driving growth and innovation in the industry.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Landscape
• Case Studies
• Technological Analysis

Global Rheumatoid Arthritis Drugs Market Size by Molecule & CAGR (2025-2032)

• Market Overview
• Pharmaceuticals
  • NSAIDs
  • Analgesics
  • DMARDs
  • Glucocorticoids
• Biopharmaceuticals
  • Biologics
    • TNF-a antagonists
    • T-cell inhibitors
    • CD20 antigen
    • JAK inhibitors
    • anti-IL6 biologics
  • Biosimilars
    • CD20 antigen
    • TNF-a antagonists

Global Rheumatoid Arthritis Drugs Market Size by Sales Channel & CAGR (2025-2032)

• Market Overview
• Prescription
• Over-the-Counter (OTC)

Global Rheumatoid Arthritis Drugs Market Size by Route of Administration & CAGR (2025-2032)

• Market Overview
• Oral
• Parenteral

Global Rheumatoid Arthritis Drugs Market Size & CAGR (2025-2032)

• North America (Molecule, Sales Channel, Route of Administration)
  • US
  • Canada
• Europe (Molecule, Sales Channel, Route of Administration)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Molecule, Sales Channel, Route of Administration)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Molecule, Sales Channel, Route of Administration)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Molecule, Sales Channel, Route of Administration)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• AbbVie Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• UCB S.A. (Belgium)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Astellas Pharma Inc. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eisai Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Chugai Pharmaceutical Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kyowa Kirin Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lupin Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zydus Lifesciences Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cipla Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dr. Reddy's Laboratories Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations